205 related articles for article (PubMed ID: 8204944)
21. Second-look laparotomy after modified posterior exenteration: patterns of persistence and recurrence in patients with stage III and stage IV ovarian cancer.
Spirtos NM; Eisenkop SM; Schlaerth JB; Ballon SC
Am J Obstet Gynecol; 2000 Jun; 182(6):1321-7. PubMed ID: 10871445
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of second cytoreductive surgery in the treatment of epithelial ovarian cancer.
Sun T; Feng Y
Chin Med J (Engl); 1998 Mar; 111(3):272-4. PubMed ID: 10374433
[TBL] [Abstract][Full Text] [Related]
23. Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma.
Tournigand C; Louvet C; Molitor JL; Dehni N; Lejeune V; Sezeur A; Pigne A; Marpeau L; Cady J; de Gramont A
Gynecol Oncol; 2001 Nov; 83(2):198-204. PubMed ID: 11606072
[TBL] [Abstract][Full Text] [Related]
24. [Experience in first-line chemotherapy with paclitaxel for the treatment of ovarian carcinomas].
Pete I; Szánthó A; Mayer A; Thurzó L; Pulay T
Orv Hetil; 2003 May; 144(19):919-24. PubMed ID: 12809068
[TBL] [Abstract][Full Text] [Related]
25. Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer.
McMeekin DS; Tillmanns T; Chaudry T; Gold M; Johnson G; Walker J; Mannel R
Gynecol Oncol; 2004 Oct; 95(1):157-64. PubMed ID: 15385126
[TBL] [Abstract][Full Text] [Related]
26. 32P following negative second-look laparotomy for epithelial ovarian cancer.
Rogers L; Varia M; Halle J; Freddo J; Qaqish B; O'Keefe T; Fowler W
Gynecol Oncol; 1993 Aug; 50(2):141-6. PubMed ID: 8375727
[TBL] [Abstract][Full Text] [Related]
27. Consolidation intraperitoneal chemotherapy in epithelial ovarian cancer patients following negative second-look laparotomy.
Tarraza HM; Boyce CR; Smith WG; Jones MA
Gynecol Oncol; 1993 Sep; 50(3):287-90. PubMed ID: 8406188
[TBL] [Abstract][Full Text] [Related]
28. High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC).
Joly F; Héron JF; Kerbrat P; Chauvergne J; Rios M; Mayer F; Chinet-Charrot P; Goupil A; Lebrun-Jezekova D; Vennin D; Lhommé C; Macé-Lesec'h J; Crouet H
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):361-8. PubMed ID: 10985895
[TBL] [Abstract][Full Text] [Related]
29. Advanced epithelial ovarian carcinoma in Thai women: should we continue to offer second-look laparotomy?
Linasmita V; Wilailak S; Thakkinstian A; Srisupundit S; Tangtrakul S; Israngura N; Bullangpoti S
J Med Assoc Thai; 2001 Jul; 84(7):958-65. PubMed ID: 11759976
[TBL] [Abstract][Full Text] [Related]
30. Second-look laparotomy for ovarian cancer provides reliable prognostic information and improves survival.
Friedman RL; Eisenkop SM; Wang HJ
Gynecol Oncol; 1997 Oct; 67(1):88-94. PubMed ID: 9345362
[TBL] [Abstract][Full Text] [Related]
31. A formula for predicting the risk of a positive second-look laparotomy in epithelial ovarian cancer: implications for a randomized trial.
Morgan MA; Noumoff JS; King S; Mikuta JJ
Obstet Gynecol; 1992 Dec; 80(6):944-8. PubMed ID: 1333064
[TBL] [Abstract][Full Text] [Related]
32. Impact of surgical approach on the management of macroscopic early ovarian borderline tumors.
Desfeux P; Camatte S; Chatellier G; Blanc B; Querleu D; Lécuru F
Gynecol Oncol; 2005 Sep; 98(3):390-5. PubMed ID: 16043215
[TBL] [Abstract][Full Text] [Related]
33. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
[TBL] [Abstract][Full Text] [Related]
34. Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group study.
Greer BE; Bundy BN; Ozols RF; Fowler JM; Clarke-Pearson D; Burger RA; Mannel R; DeGeest K; Hartenbach EM; Baergen RN; Copeland LJ
Gynecol Oncol; 2005 Oct; 99(1):71-9. PubMed ID: 16039699
[TBL] [Abstract][Full Text] [Related]
35. Second look for ovarian cancer: laparoscopy or Laparotomy? A prospective comparative study.
Clough KB; Ladonne JM; Nos C; Renolleau C; Validire P; Durand JC
Gynecol Oncol; 1999 Mar; 72(3):411-7. PubMed ID: 10053115
[TBL] [Abstract][Full Text] [Related]
36. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up.
Shapiro F; Schneider J; Markman M; Reichman BS; Venkatraman E; Barakat R; Almadrones L; Spriggs D
Gynecol Oncol; 1997 Oct; 67(1):39-45. PubMed ID: 9345354
[TBL] [Abstract][Full Text] [Related]
37. Second-look laparotomy in carcinoma of the fallopian tube.
Barakat RR; Rubin SC; Saigo PE; Lewis JL; Jones WB; Curtin JP
Obstet Gynecol; 1993 Nov; 82(5):748-51. PubMed ID: 8414320
[TBL] [Abstract][Full Text] [Related]
38. Gynecological malignancies.
Schaebler DL; Schilder RJ; Young RC
Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
[TBL] [Abstract][Full Text] [Related]
39. The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer.
Alvarez Secord A; Sayer R; Snyder SA; Broadwater G; Rodriguez GC; Berchuck A; Blackwell K
Gynecol Oncol; 2004 Jul; 94(1):74-9. PubMed ID: 15262122
[TBL] [Abstract][Full Text] [Related]
40. Combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer: updated results in a series of 120 patients.
Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1062-73. PubMed ID: 15234040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]